Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RV4421A + BS0042
- Development stage
- Phase 2
- Lead developer
- Pierre Fabre Dermo-Cosmétique
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Topical
01
Overview
RV4421A + BS0042 is a topical combination therapy developed by Pierre Fabre Dermo-Cosmétique for the management of atopic dermatitis. The product combines two proprietary active ingredients: RV4421A, a flavonoid- and saponin-rich extract from Rhealba Oat (*Avena sativa*) plantlets, and BS0042, a biotechnological extract derived from the bacterium *Aquaphilus dolomiae* (also known as I-modulia). RV4421A provides anti-inflammatory and skin-barrier-restoring properties by inhibiting the production of pro-inflammatory mediators such as thymic stromal lymphopoietin (TSLP) and interleukin-8 (IL-8). BS0042 acts as a selective antagonist of protease-activated receptor 2 (PAR-2), a key mediator of pruritus and inflammation in the skin. This combination is primarily investigated as an adjuvant to topical corticosteroids, such as desonide, to accelerate the reduction of clinical symptoms like the Local SCORAD (L-SCORAD) index and to provide a steroid-sparing effect in patients with atopic dermatitis.
- Other names
- Rhealba Oat Plantlet extract + Aquaphilus dolomiae extractI-modulia + Rhealba Oat extract
02
Targets
IL8 (C-X-C Motif Chemokine Ligand 8)PAR2 (Protease-activated receptor 2)TSLP (Thymic stromal lymphopoietin)
Beyond the preview
Go deeper on RV4421A + BS0042.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RV4421A + BS0042.